ALIVUSAlivus Life Sciences Ltd.

₹919.95-1.48%

Market Cap

₹0.00 Cr

Stock P/E

0.00

ROCE

0.00%

ROE

0.00%

Book Value

₹0.00

You might have missed

No Recent News

No recent news available for this stock.

Shareholding

Holdings

Distribution

Promoter

Institution

Others

From Last Concall

POSITIVES

•
Revenue growth driven by non-GPL segment; INR602 crores with 2.2% YoY growth, non-GPL up 14.5% YoY.
•
Gross margin expansion supports profitability; 55.1% gross margin, up 400 bps YoY.

NEGATIVES

•
GPL segment weakness; 22% YoY decline due to GPL inventory rationalization impacting overall API growth.
•
CDMO business remained subdued in the quarter, despite ongoing validation and planned commercialization in H2.

Peers Summary

Sector Leader

Alivus Life Sciences Ltd. shows no growth and zero profitability metrics, positioning it at the bottom of the sector. However, peers like Sun Pharmaceutical Industries Ltd. and Dr. Reddy's Laboratories Ltd. are strong performers with solid growth, profitability, and reasonable valuations, indicating a robust industry despite the underperformance of the target company.

Key Points

• Alivus Life Sciences Ltd. has zero revenue and profit metrics, indicating no growth or returns.
• Sun Pharmaceuticals and Dr. Reddy's Laboratories emerge as sector leaders with high ROE and revenue growth.
• Alivus is overvalued at a PE of 23.66 with no earnings, while peers show better valuations relative to their growth.

Top Performers

Sun Pharmaceutical Industries Ltd.

Strong revenue growth (8.42% YoY) and ROE (16.13%), but high PE ratio (87.59) making it less attractive on valuation.

Dr. Reddy's Laboratories Ltd.

Excellent profitability metrics with a PE of 15.50 and high ROE (21.76%), making it both a growth and value pick.

Cipla Ltd.

Strong growth (13.28% YoY) and low PE (23.73) with solid ROE (16.63%), indicating a balanced position.

Explore

Watchlists